Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 5, 2010, Pages 438-444

  Vogelmeier, C ^a   Verkindre, C ^b   Cheung, D ^c   Galdiz, J B ^d   Guclu S Z ^e   Spangenthal, S ^f   Overend, T ^g   Henley, M ^g   Mizutani, G ^g   Zeldin, R K ^h  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Hopital de Bethune   (France)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d HOSPITAL DE CRUCES   (Spain)

^e Dr Suat Seren Pulmonary Hospital   (Turkey)

^f American Health Research   (United States)

^g NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Muscarinic antagonist; NVA237; Once daily

Indexed keywords

GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMATOLOGY; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPYRROLATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77955418463     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.04.005     Document Type: Article

References (17)

1. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Available at: <>http://goldcopd.com.
2. Cuvelier A., Muir J.F., Benhamou D., Weitzenblum E., Zuck P., Delacenserie R., et al. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients. Respir Care 2002, 47:159-166.
3. Taylor J., Kotch A., Rice K., Ghafouri M., Kurland C.L., Fagan N.M., et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001, 120:1253-1261.
4. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
5. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., Cornelissen P.J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch tiotropium study group. Thorax 2000, 55:289-294.
6. Kuna P., Vinkler I., Overend T., Snape S., Tansley R. Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur Respir J 2007, 30(Suppl. 51). P2135 (Abstract).
7. Singh D., Corris P.A., Tansley R. NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. Eur Respir J 2006, 28(Suppl. 50). P3051 (Abstract).
8. Overend T., Fukuchi Y., Flémale A., Verkindre C., Takeda A., Johnson J., et al. Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD. Eur Respir J 2008, 32(Suppl. 52). P3606 (Abstract).
9. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2006. Available at: <>http://goldcopd.com.
10. Pavkov R., Singh D., Reitveld I. Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. Respir Drug Deliv 2008, 3:683-686.
11. Ali-Melkkila T., Kanto J., Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993, 37:633-642.
12. Thomas R., Eltringham E., Tansley R., Snape S. Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans. Eur Respir J 2006, 28(Suppl. 50). P3837 (Abstract).
13. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124.
14. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
15. Casaburi R., Briggs D.D., Donohue J.F., Serby C.W., Menjoge S.S., Witek T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. Chest 2000, 118:1294-1302.
16. Tashkin D.P. Multiple dose regimens. Impact on compliance. Chest 1995, 107:176S-182S.
17. Restrepo R.D., Alvarez M.T., Wittnebel L.D., Sorenson H., Wettstein R., Vines D.L., et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:371-384.